SuperworthBoston Scientific Corporation BSX
Medical - Devices, Healthcare
$41.58
−1.45%
- Market cap
- $60.3B
- PE
- 16.8×
- 10y median 66.3×
- Forward PE
- Price to sales
- 2.9×
- EV/EBIT
- 16.8×
- Revenue, 12 months
- $21B
- +14% on a year ago
- Net margin
- 17.5%
- Free cash flow yield
- 6.0%
Boston Scientific trades at 16.8× trailing earnings, cheaper than 90% of the last ten years. Revenue was $21B over the last twelve months, up 14% on a year earlier with a 17% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.7B | $3.9B | $4.1B | $4.2B | $4.6B+22% | $4.7B+21% | $5.1B+23% | $5.1B+20% | $5.3B+16% | $5.2B+12% | $5.4B+8% | |
| Cost of revenue | $1.1B | $1.2B | $1.3B | $1.3B | $1.5B+28% | $1.5B+20% | $1.6B+29% | $1.5B+16% | $1.6B+10% | $1.6B+9% | $1.6B−3% |
| Gross profit | $2.6B | $2.6B | $2.9B | $2.9B | $3.1B+20% | $3.2B+21% | $3.4B+20% | $3.5B+22% | $3.7B+19% | $3.6B+13% | $3.8B+12% |
| R&D | $363M | $366M | $383M | $407M | $459M+26% | $443M+21% | $526M+37% | $514M+26% | $569M+24% | $516M+17% | $554M+5% |
| SG&A | $1.4B | $1.4B | $1.4B | $1.6B | $1.6B+17% | $1.6B+17% | $1.7B+19% | $1.7B+12% | $1.8B+14% | $1.8B+12% | $1.8B+5% |
| $584M | $675M | $520M | $733M | $675M+16% | $921M+36% | $819M+58% | $1B+43% | $825M+22% | $1.1B+20% | $1.2B+44% | |
| Interest expense | $67M | $72M | $81M | $83M | $139M+108% | $87M+21% | $90M+11% | $87M+5% | $90M−35% | $90M+3% | $96M+7% |
| Pre-tax income | $505M | $608M | $420M | $669M | $585M+16% | $805M+32% | $941M+124% | $939M+40% | $700M+20% | $1.2B+44% | $1.1B+13% |
| $1M | $115M | $98M | $200M | $23M+2200% | $133M+16% | $146M+49% | $183M−9% | $30M+30% | −$176M | $155M+6% | |
| Net income | $504M | $493M | $324M | $468M | $566M+12% | $672M+36% | $795M+145% | $755M+61% | $670M+18% | $1.3B+99% | $905M+14% |
| $0.34 | $0.33 | $0.22 | $0.32 | $0.38+11% | $0.45+36% | $0.53+141% | $0.51+59% | $0.45+19% | $0.90+100% | $0.61+15% | |
| 1.5B | 1.5B | 1.5B | 1.5B | 1.5B+1% | 1.5B+1% | 1.5B+1% | 1.5B+1% | 1.5B+0% | 1.5B+0% | 1.5B−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Devices within ten times Boston Scientific's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BSXBoston Scientific Corporation | $60.3B | 16.8× | 66.3× | 2.9× | +14% | 17.5% | |
| EWEdwards Lifesciences Corporation | $49.4B | 49.3× | 40.5× | 7.6× | +15% | 15.4% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| ABTAbbott Laboratories | $170.8B | 31.8× | 36.2× | 3.7× | +8% | 11.6% | |
| Peer median | $77.5B | 30.2× | 38.3× | 3.9× | +9% | 14.2% |
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .